The University of Southampton
University of Southampton Institutional Repository

Routine pressure wire assessment versus conventional angiography in the management of patients with coronary artery disease: The RIPCORD 2 Trial

Routine pressure wire assessment versus conventional angiography in the management of patients with coronary artery disease: The RIPCORD 2 Trial
Routine pressure wire assessment versus conventional angiography in the management of patients with coronary artery disease: The RIPCORD 2 Trial

Background: Measurement of fractional flow reserve (FFR) has an established role in guiding percutaneous coronary intervention. We tested the hypothesis that, at the stage of diagnostic invasive coronary angiography, systematic FFR-guided assessment of coronary artery disease would be superior, in terms of resource use and quality of life, to assessment by angiography alone. Methods: We performed an open-label, randomized, controlled trial in 17 UK centers, recruiting 1100 patients undergoing invasive coronary angiography for the investigation of stable angina or non-ST-segment-elevation myocardial infarction. Patients were randomized to either angiography alone (angiography) or angiography with systematic pressure wire assessment of all epicardial vessels >2.25 mm in diameter (angiography+FFR). The coprimary outcomes assessed at 1 year were National Health Service hospital costs and quality of life. Prespecified secondary outcomes included clinical events. Results: In the angiography+FFR arm, the median number of vessels examined was 4 (interquartile range, 3-5). The median hospital costs were similar: angiography, £4136 (interquartile range, £2613-£7015); and angiography+FFR, £4510 (£2721-£7415; P=0.137). There was no difference in median quality of life using the visual analog scale of the EuroQol EQ-5D-5L: angiography, 75 (interquartile range, 60-87); and angiography+FFR, 75 (interquartile range, 60-90; P=0.88). The number of clinical events was as follows: deaths, 5 versus 8; strokes, 3 versus 4; myocardial infarctions, 23 versus 22; and unplanned revascularizations, 26 versus 33, with a composite hierarchical event rate of 8.7% (48 of 552) for angiography versus 9.5% (52 of 548) for angiography+FFR (P=0.64). Conclusions: A strategy of systematic FFR assessment compared with angiography alone did not result in a significant reduction in cost or improvement in quality of life. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01070771.

coronary angiography, costs and cost analysis, physiology, quality of life, randomized controlled trial
0009-7322
687-698
Stables, R
56d25cc7-7f4a-45a2-ab15-1b5ebf610d8a
Mullen, L
8b6e95ba-6b39-4f70-8747-8533585fc647
Elguindy, M
c2894cbb-b1fe-4bae-84c7-555e3799bd1c
Nicholas, Z
11456680-13ee-4481-a8a5-2c6a3df3fe30
Aboul-Enien, Y
59a8e521-7da8-41f9-9cf6-08a156cd92fc
Kemp, I
aa9fd5f4-4367-4d3b-a9aa-39582eb31acc
O'Kane, P
2861c038-65f3-407c-a1c2-345b7325e961
Hobson, A
7e4ba8c2-3c3d-4f30-855c-20d81aac0801
Johnson, T.
1c3ef99a-c67b-4482-ba75-8efa73222878
Khan, S.
0afabaf7-e0d0-48e0-851c-5745639bdfc2
Wheatcroft, S.
11c055b8-7ad7-4e2b-87e7-d6bad1b2f070
Garg, S.
b7d2f3c4-499f-4457-9633-b26295deda30
Zaman, A.
b943cf7b-900b-4ae8-a29f-c626cec3442e
Mamas, Mamas A.
41515b72-75ff-4922-bb9f-8f9c63f9f5af
Nolan, J.
e12a7ca8-681e-4b48-98be-252001fe2f68
Jadhav, S.
65eb5e96-f423-42b4-8226-d11dd0863e5a
Berry, C.
194706e7-6f54-4240-9f5d-af2db991a16e
Watkins, S.
b35c9e17-2eab-44c4-a4ea-c5b3588e4031
Hildick-Smith, D.
511ddc70-0414-40bb-9487-028bd90cf23d
Gunn, J.
f3ec8672-33ca-408f-9663-35fb0b9da694
Conway, D.
04897f0e-0050-4d6a-baf1-62dfa6b848ba
Hoye, A.
e86a4238-b82b-426a-9214-18d2729a7b27
Fazal, I.
9ac613cb-d409-40b8-929a-7bc2ca42b24f
Hanratty, C.
b45f4515-e62a-472b-b02a-e3577ecbe93a
De Bruyne, B.
b5bc4cf9-5ca9-4d9e-b48b-cbaa83727720
Curzen, Nicholas
70f3ea49-51b1-418f-8e56-8210aef1abf4
Stables, R
56d25cc7-7f4a-45a2-ab15-1b5ebf610d8a
Mullen, L
8b6e95ba-6b39-4f70-8747-8533585fc647
Elguindy, M
c2894cbb-b1fe-4bae-84c7-555e3799bd1c
Nicholas, Z
11456680-13ee-4481-a8a5-2c6a3df3fe30
Aboul-Enien, Y
59a8e521-7da8-41f9-9cf6-08a156cd92fc
Kemp, I
aa9fd5f4-4367-4d3b-a9aa-39582eb31acc
O'Kane, P
2861c038-65f3-407c-a1c2-345b7325e961
Hobson, A
7e4ba8c2-3c3d-4f30-855c-20d81aac0801
Johnson, T.
1c3ef99a-c67b-4482-ba75-8efa73222878
Khan, S.
0afabaf7-e0d0-48e0-851c-5745639bdfc2
Wheatcroft, S.
11c055b8-7ad7-4e2b-87e7-d6bad1b2f070
Garg, S.
b7d2f3c4-499f-4457-9633-b26295deda30
Zaman, A.
b943cf7b-900b-4ae8-a29f-c626cec3442e
Mamas, Mamas A.
41515b72-75ff-4922-bb9f-8f9c63f9f5af
Nolan, J.
e12a7ca8-681e-4b48-98be-252001fe2f68
Jadhav, S.
65eb5e96-f423-42b4-8226-d11dd0863e5a
Berry, C.
194706e7-6f54-4240-9f5d-af2db991a16e
Watkins, S.
b35c9e17-2eab-44c4-a4ea-c5b3588e4031
Hildick-Smith, D.
511ddc70-0414-40bb-9487-028bd90cf23d
Gunn, J.
f3ec8672-33ca-408f-9663-35fb0b9da694
Conway, D.
04897f0e-0050-4d6a-baf1-62dfa6b848ba
Hoye, A.
e86a4238-b82b-426a-9214-18d2729a7b27
Fazal, I.
9ac613cb-d409-40b8-929a-7bc2ca42b24f
Hanratty, C.
b45f4515-e62a-472b-b02a-e3577ecbe93a
De Bruyne, B.
b5bc4cf9-5ca9-4d9e-b48b-cbaa83727720
Curzen, Nicholas
70f3ea49-51b1-418f-8e56-8210aef1abf4

Stables, R, Mullen, L, Elguindy, M, Nicholas, Z, Aboul-Enien, Y, Kemp, I, O'Kane, P, Hobson, A, Johnson, T., Khan, S., Wheatcroft, S., Garg, S., Zaman, A., Mamas, Mamas A., Nolan, J., Jadhav, S., Berry, C., Watkins, S., Hildick-Smith, D., Gunn, J., Conway, D., Hoye, A., Fazal, I., Hanratty, C., De Bruyne, B. and Curzen, Nicholas (2022) Routine pressure wire assessment versus conventional angiography in the management of patients with coronary artery disease: The RIPCORD 2 Trial. Circulation, 146 (9), 687-698. (doi:10.1161/CIRCULATIONAHA.121.057793).

Record type: Article

Abstract

Background: Measurement of fractional flow reserve (FFR) has an established role in guiding percutaneous coronary intervention. We tested the hypothesis that, at the stage of diagnostic invasive coronary angiography, systematic FFR-guided assessment of coronary artery disease would be superior, in terms of resource use and quality of life, to assessment by angiography alone. Methods: We performed an open-label, randomized, controlled trial in 17 UK centers, recruiting 1100 patients undergoing invasive coronary angiography for the investigation of stable angina or non-ST-segment-elevation myocardial infarction. Patients were randomized to either angiography alone (angiography) or angiography with systematic pressure wire assessment of all epicardial vessels >2.25 mm in diameter (angiography+FFR). The coprimary outcomes assessed at 1 year were National Health Service hospital costs and quality of life. Prespecified secondary outcomes included clinical events. Results: In the angiography+FFR arm, the median number of vessels examined was 4 (interquartile range, 3-5). The median hospital costs were similar: angiography, £4136 (interquartile range, £2613-£7015); and angiography+FFR, £4510 (£2721-£7415; P=0.137). There was no difference in median quality of life using the visual analog scale of the EuroQol EQ-5D-5L: angiography, 75 (interquartile range, 60-87); and angiography+FFR, 75 (interquartile range, 60-90; P=0.88). The number of clinical events was as follows: deaths, 5 versus 8; strokes, 3 versus 4; myocardial infarctions, 23 versus 22; and unplanned revascularizations, 26 versus 33, with a composite hierarchical event rate of 8.7% (48 of 552) for angiography versus 9.5% (52 of 548) for angiography+FFR (P=0.64). Conclusions: A strategy of systematic FFR assessment compared with angiography alone did not result in a significant reduction in cost or improvement in quality of life. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01070771.

Text
RIPCORD2_Circulation_ChangesTracked_20220531 - Accepted Manuscript
Download (70kB)

More information

Accepted/In Press date: 14 June 2022
e-pub ahead of print date: 10 August 2022
Published date: 30 August 2022
Additional Information: Funding Information: Dr Berry is employed by the University of Glasgow, which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health. Dr Mamas has received unrestricted educational grants from Terumo, Boston Scientific, Abbott, and Medtronic in the past 24 months. Dr De Bruyne has a consulting relationship with Boston Scientific, Abbott Vascular, CathWorks, Siemens, and Coroventis Research; receives research grants from Abbott Vascular, Coroventis Research, Cathworks, and Boston Scientific; and holds minor equities in Philips-Volcano, Siemens, GE Healthcare, Edwards Life Sciences, HeartFlow, Opsens, and Celiad. Dr Curzen has received unrestricted grants from HeartFlow, Boston Scientific, and Beckmann Coulter; speaker fees/consultancy from HeartFlow, Boston Scientific, Abbott, and Edwards; and travel sponsorship from HeartFlow, Biosensors, Edwards, and Medtronic. Dr Stables has received unrestricted grants from Medtronic and BioLife; speaker fees/consultancy from Boston Scientific, Abbott, Medtronic, and Edwards; and travel sponsorship from Boston Scientific. Dr Wheatcroft has received speaker fees/consultancy from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, and Novo Nordisk and travel sponsorship from Abbott Vascular, Boston Scientific, and Medtronic. The other authors report no conflicts. Funding Information: The trial was investigator-initiated and funded by an unrestricted research grant from Boston Scientific Corporation. Dr Berry is supported by the British Heart Foundation ((RE/18/6134217) Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.
Keywords: coronary angiography, costs and cost analysis, physiology, quality of life, randomized controlled trial

Identifiers

Local EPrints ID: 467626
URI: http://eprints.soton.ac.uk/id/eprint/467626
ISSN: 0009-7322
PURE UUID: fbaa4960-2743-4990-82fa-72f60fc53c59
ORCID for Nicholas Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 15 Jul 2022 19:21
Last modified: 17 Mar 2024 07:23

Export record

Altmetrics

Contributors

Author: R Stables
Author: L Mullen
Author: M Elguindy
Author: Z Nicholas
Author: Y Aboul-Enien
Author: I Kemp
Author: P O'Kane
Author: A Hobson
Author: T. Johnson
Author: S. Khan
Author: S. Wheatcroft
Author: S. Garg
Author: A. Zaman
Author: Mamas A. Mamas
Author: J. Nolan
Author: S. Jadhav
Author: C. Berry
Author: S. Watkins
Author: D. Hildick-Smith
Author: J. Gunn
Author: D. Conway
Author: A. Hoye
Author: I. Fazal
Author: C. Hanratty
Author: B. De Bruyne
Author: Nicholas Curzen ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×